Last reviewed · How we verify

Moxifloxacin and Cobicistat

Food and Drug Administration (FDA) · Phase 1 active Small molecule

Moxifloxacin and Cobicistat is a Small molecule drug developed by Food and Drug Administration (FDA). It is currently in Phase 1 development. Also known as: Treatment F.

At a glance

Generic nameMoxifloxacin and Cobicistat
Also known asTreatment F
SponsorFood and Drug Administration (FDA)
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Moxifloxacin and Cobicistat

What is Moxifloxacin and Cobicistat?

Moxifloxacin and Cobicistat is a Small molecule drug developed by Food and Drug Administration (FDA).

Who makes Moxifloxacin and Cobicistat?

Moxifloxacin and Cobicistat is developed by Food and Drug Administration (FDA) (see full Food and Drug Administration (FDA) pipeline at /company/food-and-drug-administration-fda).

Is Moxifloxacin and Cobicistat also known as anything else?

Moxifloxacin and Cobicistat is also known as Treatment F.

What development phase is Moxifloxacin and Cobicistat in?

Moxifloxacin and Cobicistat is in Phase 1.

Related